233 related articles for article (PubMed ID: 36347432)
1. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.
Sun R; Xiang J; Zhou Q; Piao Y; Tang J; Shao S; Zhou Z; Bae YH; Shen Y
Adv Drug Deliv Rev; 2022 Dec; 191():114614. PubMed ID: 36347432
[TBL] [Abstract][Full Text] [Related]
2. Transcytosis-enabled active extravasation of tumor nanomedicine.
Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
[TBL] [Abstract][Full Text] [Related]
3. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
Dhaliwal A; Zheng G
Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
5. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
Kim J; Cho H; Lim DK; Joo MK; Kim K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
[TBL] [Abstract][Full Text] [Related]
6. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
7. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
[TBL] [Abstract][Full Text] [Related]
8. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
9. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
[TBL] [Abstract][Full Text] [Related]
10. An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy.
Wu H; Li W; Hao M; Wang Y; Xue L; Ju C; Zhang C
Adv Drug Deliv Rev; 2022 Aug; 187():114380. PubMed ID: 35662610
[TBL] [Abstract][Full Text] [Related]
11. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
Maeda H
Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
[TBL] [Abstract][Full Text] [Related]
13. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
15. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
[TBL] [Abstract][Full Text] [Related]
16. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
[TBL] [Abstract][Full Text] [Related]
17. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
18. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
Fang J; Islam W; Maeda H
Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
[TBL] [Abstract][Full Text] [Related]
19. Tumor targeting via EPR: Strategies to enhance patient responses.
Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
[TBL] [Abstract][Full Text] [Related]
20. Platinum-based combination nanomedicines for cancer therapy.
Li Y; Lin W
Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
